Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMVJ21
|
|||
| Drug Name |
URO-902
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Overactive bladder [ICD-11: GC50.0; ICD-10: N32.8; ICD-9: 596.51] | Phase 2 | [1] | |
| Company |
Urovant Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium-activated potassium channel KCa1.1 (KCNMA1) | Target Info | . | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Vascular smooth muscle contraction | ||||
| Insulin secretion | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Reactome | cGMP effects | |||
| WikiPathways | Potassium Channels | |||
| Platelet homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04211831) An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence. U.S.National Institutes of Health. | |||
| REF 2 | Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn. 2020 Feb;39(2):744-753. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.